June 2022 in “Pakistan Journal of Medical and Health Sciences” This randomized controlled trial found that topical clobetasol propionate 0.05% ointment is significantly more effective than topical tacrolimus 0.1% ointment in promoting hair regrowth in patients with alopecia areata, with effective results observed in 79.31% of clobetasol users compared to 44.82% of tacrolimus users.
July 2025 in “Pakistan Journal of Intensive Care Medicine” In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
10 citations
,
April 2020 in “Dermatology and therapy” In this study of 35 patients with scalp alopecia areata, calcipotriol ointment led to faster and greater hair regrowth than clobetasol, though differences were not statistically significant.
July 2022 in “المجلة العراقية للصيدلة” This study reported that topical azelaic acid cream 20% demonstrated statistically significant efficacy in treating localized alopecia areata of the scalp over 12 weeks, comparable to topical clobetasol ointment 0.05%, suggesting it as a potential therapeutic option.